Biomarkers in Acute Severe Ulcerative Colitis

  • Matthew C. Choy
  • Dean Seah
  • Peter De Cruz


This chapter will cover prognostic and predictive biomarkers in acute severe ulcerative colitis (ASUC) that have been used to predict steroid response/failure and salvage therapy response/failure. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.


  1. 1.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–8.CrossRefGoogle Scholar
  2. 2.
    Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–7.CrossRefGoogle Scholar
  3. 3.
    Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879–87.CrossRefGoogle Scholar
  4. 4.
    Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477–91.CrossRefGoogle Scholar
  5. 5.
    Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935–45.CrossRefGoogle Scholar
  6. 6.
    Cesarini M, Collins GS, Ronnblom A, Santos A, Wang LM, Sjoberg D, et al. Predicting the individual risk of acute severe colitis at diagnosis. J Crohns Colitis. 2016;11:335–41.PubMedCentralGoogle Scholar
  7. 7.
    Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–10.CrossRefGoogle Scholar
  8. 8.
    Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.CrossRefGoogle Scholar
  9. 9.
    Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–6.PubMedGoogle Scholar
  10. 10.
    Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–87.CrossRefGoogle Scholar
  11. 11.
    Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, et al. CRP/Albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol. 2018;52(6):e48–52.Google Scholar
  12. 12.
    Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, et al. Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis: prospective cohort study. J Crohns Colitis. 2017;11:1309–16.CrossRefGoogle Scholar
  13. 13.
    Choy MC, Boyd K, Burder R, Gorelik A, Nallas R, Horvath J, et al. P511 Early prediction of steroid failure in acute severe ulcerative colitis. J Crohns Colitis. 2018;12:S363–S.CrossRefGoogle Scholar
  14. 14.
    Singh S, Al-Darmaki A, Frolkis AD, Seow CH, Leung Y, Novak KL, et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149:928–37.CrossRefGoogle Scholar
  15. 15.
    Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.CrossRefGoogle Scholar
  16. 16.
    Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.CrossRefGoogle Scholar
  17. 17.
    Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.CrossRefGoogle Scholar
  18. 18.
    Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237–43.CrossRefGoogle Scholar
  19. 19.
    Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.CrossRefGoogle Scholar
  20. 20.
    Christensen B, Goeppinger SR, Colman R, Siddiqui D, Yarur A, Hirsch A, Bochenek AA, Wichmann A, Sakuraba A, Cohen R, Rubin DT. P404. Calcineurin inhibitors are safe and effective for induction of remission in patients commencing vedolizumab for IBD. J Crohns Colitis. 2015;9:S281–S.Google Scholar
  21. 21.
    Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.CrossRefGoogle Scholar
  22. 22.
    Aceituno M, Garcia-Planella E, Heredia C, Zabana Y, Feu F, Domenech E, et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis. 2008;14:347–52.CrossRefGoogle Scholar
  23. 23.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.CrossRefGoogle Scholar
  24. 24.
    Choy MC, Seah D, Faleck DM, Shah SC, Al-Khoury A, An YK, et al. P542 Infliximab salvage therapy in acute severe ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis. 2018;12:S379–S80.CrossRefGoogle Scholar
  25. 25.
    Brandse JF, Mathot RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251-8.e1–2.CrossRefGoogle Scholar
  26. 26.
    Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.CrossRefGoogle Scholar
  27. 27.
    Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–94; author reply 95.CrossRefGoogle Scholar
  28. 28.
    Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33(7):1347–52.CrossRefGoogle Scholar
  29. 29.
    Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673–8.CrossRefGoogle Scholar
  30. 30.
    Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037–53.CrossRefGoogle Scholar
  31. 31.
    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.CrossRefGoogle Scholar
  32. 32.
    Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohns Colitis. 2018;12:289–97.CrossRefGoogle Scholar
  33. 33.
    Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–5.e2. LID - S0016-5085(15)00572-7 [pii] LID - 10.1053/j.gastro.2015.04.016 [doi].CrossRefGoogle Scholar
  34. 34.
    Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, et al. Clinical response and complications are not associated with drug levels in patients with severe ulcerative colitis on IV cyclosporine induction therapy. Inflamm Bowel Dis. 2018;24:1291–7.CrossRefGoogle Scholar
  35. 35.
    Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698–707.CrossRefGoogle Scholar
  36. 36.
    Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296–307.e5.CrossRefGoogle Scholar
  37. 37.
    Olsen T, Goll R, Cui G, Christiansen I, Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46:222–7.CrossRefGoogle Scholar
  38. 38.
    Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–55.CrossRefGoogle Scholar
  39. 39.
    Dahlen R, Magnusson MK, Bajor A, Lasson A, Ung KA, Strid H, et al. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy. Scand J Gastroenterol. 2015;50(9):1118–26.CrossRefGoogle Scholar
  40. 40.
    Jurgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–9.CrossRefGoogle Scholar
  41. 41.
    Daniel F, Loriot MA, Seksik P, Cosnes J, Gornet JM, Lemann M, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19–23.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Matthew C. Choy
    • 1
    • 2
    • 3
  • Dean Seah
    • 1
  • Peter De Cruz
    • 1
    • 4
  1. 1.Department of GastroenterologyAustin HospitalMelbourneAustralia
  2. 2.Department of GastroenterologySt Vincent’s HospitalFitzroyAustralia
  3. 3.Department of MedicineAustin Academic Centre, University of MelbourneMelbourneAustralia
  4. 4.Department of MedicineThe University of MelbourneMelbourneAustralia

Personalised recommendations